Next-generation ADCs

About Sutro Biopharma

Sutro Biopharma is redefining cancer therapy through its innovative cell-free protein synthesis platform, XpressCF®, which allows for the rational design of optimized antibody-drug conjugates (ADCs). The company's core strategy involves developing single- and dual-payload ADCs aimed at overcoming treatment resistance and expanding the range of treatable tumors. With a public listing on NASDAQ and a leadership team rich in biotech experience, Sutro is advancing a clinical pipeline while leveraging its platform through strategic collaborations to create meaningful breakthroughs for patients.

Therapeutic Areas

Other Undisclosed cancers Drugs